Table 4.
MDA components in women (n=226) and men (n=226) with PsA by treatment target state
| Target status | MDA met (at target) | MDA not met (not at target) | ||||
|---|---|---|---|---|---|---|
| MDA variables N(%) | Women (n=58) | Men (n=113) | p-value | Women (n=168) | Men (n=113) | p-value |
| TJC68 ≤1 | 56 (96.6) | 105 (92.9) | 0.341 | 41 (36.3) | 41 (36.3) | 0.174 |
| SJC66 ≤1 | 54 (93.1) | 106 (93.8) | 0.863 | 58 (51.3) | 59 (50.4) | 0.248 |
| LEI ≤1 | 56 (96.6) | 110 (97.3) | 0.320 | 120 (71.4) | 92 (81.4) | 0.087 |
| Pain VAS ≤1.5 | 32 (55.2) | 65 (57.5) | 0.771 | 4 (2.4) | 1 (0.9) | 0.355 |
| Patient global VAS≤2 | 33 (56.9) | 85 (75.2) | 0.011 | 16 (9.5) | 13 (11.5) | 0.594 |
| HAQ-DI ≤0.5 | 50 (86.2) | 110 (97.3) | 0.005 | 34 (20.2) | 41 (36.3) | 0.003 |
| BSA =0 | 29 (50.0) | 48 (42.5) | 0.352 | 53 (31.5) | 30 (26.5) | 0.369 |
| BSA >0 and ≤5 | 26 (44.8) | 63 (55.8) | 0.178 | 87 (51.8) | 57 (50.4) | 0.826 |
Bold font designates significant p-values. Abbreviations: TJC68 tender joint count range 0–68, SJC66 swollen joint count range 0–66, LEI Leeds enthesitis index range 0–6, VAS visual analog scale range 0–10, HAQ-DI Health Assessment Questionnaire Disability index range 0–3, BSA body surface area range 0–100%, bDMARD biologic Disease Modifying Rheumatic Drug.
Missing values for (women, men): TJC68 (0,2), SJC66 (0,2), Pain VAS (1,1), Patient global VAS (1,2)